Payment overview · 2025
General Payments
$941.14
44 reported records · 17 companies
Healthcare provider profile · identity verified
Bochen Tong, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · RICHMOND, TX · NPI 1689092611
Verified facts
What the public records show
CMS Open Payments records show Bochen Tong, M.D. received $941.14 in general payments during 2025 across 44 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 32.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $307.58 | 32.7% | 11 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $75.17 | 8.0% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $72.39 | 7.7% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $62.12 | 6.6% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $61.93 | 6.6% | 3 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $60.62 | 6.4% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $49.49 | 5.3% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $48.49 | 5.2% | 2 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $35.58 | 3.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $32.82 | 3.5% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $28.71 | 3.0% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $24.92 | 2.6% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.73 | 2.5% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $15.54 | 1.6% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.05 | 1.5% | 1 | 2025 |
| Renalytix AI, Inc. | Unresolved — no canonical attribution shown | $14.01 | 1.5% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $13.99 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $941.14 | 44 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $307.58 | 11 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $62.12 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $62.12 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $61.93 | 3 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $60.62 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $54.14 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $51.68 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $49.49 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $48.49 | 2 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $35.58 | 2 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $35.58 | 2 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $35.58 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $32.82 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $28.71 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $28.71 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $24.92 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $24.92 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $23.73 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $21.03 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $15.54 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.05 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $14.05 | 1 | 2025 |
Source payment records
|
|||||
| KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT Normalized: kidneyintelx blood collection convenience kit |
Device | Renalytix AI, Inc. | $14.01 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $13.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 44 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 50 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
38 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
50 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
44 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
23 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 284 | 99 |
| Amlodipine Besylate | Amlodipine Besylate | 196 | 62 |
| Lisinopril | Lisinopril | 140 | 50 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 135 | 52 |
| Levothyroxine Sodium | Levothyroxine Sodium | 128 | 43 |
| Losartan Potassium | Losartan Potassium | 128 | 46 |
| Pantoprazole Sodium | Pantoprazole Sodium | 97 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 95 | 32 |
| Alprazolam | Alprazolam | 89 | 28 |
| Furosemide | Furosemide | 85 | 35 |
| Gabapentin | Gabapentin | 85 | 37 |
| Metformin Hcl | Metformin Hcl | 85 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 85 | 36 |
| Methylprednisolone | Methylprednisolone | 83 | 69 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 80 | 41 |
| Trazodone Hcl | Trazodone Hcl | 71 | 27 |
| Azithromycin | Azithromycin | 67 | 48 |
| Fluticasone Propionate | Fluticasone Propionate | 59 | 24 |
| Meloxicam | Meloxicam | 59 | 26 |
| Montelukast Sodium | Montelukast Sodium | 53 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 53 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 51 | 21 |
| Omeprazole | Omeprazole | 51 | 20 |
| Jardiance | Empagliflozin | 50 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 49 | 18 |
| Finasteride | Finasteride | 49 | 22 |
| Prednisone | Prednisone | 48 | 30 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 46 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 45 | 19 |
| Eliquis | Apixaban | 44 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 44 | 14 |
| Pregabalin | Pregabalin | 44 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 43 | 32 |
| Glipizide Er | Glipizide | 41 | 14 |
| Simvastatin | Simvastatin | 41 | 17 |
| Tramadol Hcl | Tramadol Hcl | 41 | 19 |
| Sertraline Hcl | Sertraline Hcl | 40 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 39 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 39 | 15 |
| Synthroid | Levothyroxine Sodium | 38 | 11 |
| Carvedilol | Carvedilol | 37 | 12 |
| Ezetimibe | Ezetimibe | 35 | 12 |
| Donepezil Hcl | Donepezil Hcl | 34 | 14 |
| Nifedipine Er | Nifedipine | 33 | suppressed |
| Allopurinol | Allopurinol | 31 | 11 |
| Clonazepam | Clonazepam | 31 | suppressed |
| Celecoxib | Celecoxib | 30 | 13 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 30 | suppressed |
| Eszopiclone | Eszopiclone | 29 | suppressed |
| Glipizide | Glipizide | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | suppressed |
| Ozempic | Semaglutide | 27 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 27 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 24 | 12 |
| Atenolol | Atenolol | 23 | suppressed |
| Glimepiride | Glimepiride | 23 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 23 | 19 |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Temazepam | Temazepam | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | 12 |
| Lovastatin | Lovastatin | 21 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 21 | 21 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 20 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 18 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 16 |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Mounjaro | Tirzepatide | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 14 |
| Estradiol | Estradiol | 17 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 17 | suppressed |
| Lorazepam | Lorazepam | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 17 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Fluocinonide | Fluocinonide | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 14 | 14 |
| Linzess | Linaclotide | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Praluent Pen | Alirocumab | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 12 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 11 |
| Brilinta | Ticagrelor | 12 | suppressed |
| Famotidine | Famotidine | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $941.14 · 44 records | Bayer Healthcare Pharmaceuticals Inc. | AIRSUPRA, BREZTRI, CAPLYTA, CAPVAXIVE, Dexcom G6 Transmitter, ELIQUIS, FREESTYLE LIBRE 3, Flector, GARDASIL 9, JARDIANCE, KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT, Kerendia, Licart, NEXLETOL, NURTEC ODT, NUZYRA, OTEZLA, QULIPTA, REPATHA, Tirosint, UBRELVY, Wegovy, XIFAXAN, XYOSTED | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error